PHILADELPHIA, Feb. 23, 2026 /PRNewswire/ — National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the “Class Period”).
Investor Deadline: Investors who purchased uniQure securities during the Class Period may, no later than April 13, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
uniQure, headquartered in Amsterdam, the Netherlands, is a biotechnology company focused on the development of gene therapies for severe diseases, including Huntington’s disease (HD).
The Complaint alleges that during the Class Period, Defendants misrepresented and/or failed to disclose that: (1) the design of uniQure’s Pivotal Study of its drug AMT-130 to treat HDwas not fully approved by the FDA, including comparing results to the ENROLL-HD external historical data set; and (2) Defendants downplayed the likelihood that uniQure would have to delay its BLA timeline to perform additional studies.
On November 3, 2025, uniQure disclosed that the FDA did not agree that the Phase I/II data could serve as primary evidence for a BLA submission and that the timing of a BLA submission for AMT-130 was now unclear. This caused the Company’s stock to fall more than 49%, from a closing price of $67.69 per share on October 31, 2025 to a close of $34.29 per share on November 3, 2025, the next trading day.
If you are a uniQure investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
For more information or to discuss your rights, please contact:
Andrew Abramowitz
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nasdaq-qure-investor-alert-berger-montague-advises-uniqure-nv-nasdaq-qure-investors-of-an-april-13-2026-deadline-302694124.html
SOURCE Berger Montague
